Laboratory animals as surrogate models of human obesity

Acta Pharmacologica Sinica

Volumn 33, Issue 2, 2012, Pages 173-181

  Nilsson, Cecilia ^a   Raun, Kirsten ^a   Yan, Fei Fei ^a   Larsen, Marianne O ^a   Tang Christensen, Mads ^a  

^a SIBS Novo Nordisk Translational Research Centre for PreDiabetes   (China)

Author keywords

animal models; diet induced obesity models; KK AY mice; liraglutide; ob ob mice; obesity; sibutramine; Zucker rat

Indexed keywords

EXENDIN 4; RECOMBINANT LEPTIN; SIBUTRAMINE;

APPETITE; CALORIC INTAKE; ENERGY EXPENDITURE; EXPERIMENTAL ANIMAL; FOOD INTAKE; INSULIN RESISTANCE; MINIPIG; MOUSE STRAIN; NONHUMAN; OBESITY; REVIEW; SPRAGUE DAWLEY RAT; TALLYHO MOUSE; WEIGHT REDUCTION; WISTAR RAT; ZUCKER RAT;

ANIMALS; DIET; DISEASE MODELS, ANIMAL; HUMANS; MICE; OBESITY; RATS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84856947298     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.203     Document Type: Review

References (89)

1. Padwal RS, Jajumdar SR. Drug treatments for obesity; orlistat sibutramine and rimonabant. Lancet 2007; 369: 71-7. (Pubitemid 46027230)
2. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-16.
3. Finer N. Executive steering committee of the sibutramine cardiovascular outcome trial. Withdrawal of sibutramine. Editorial is judgement in advance of the facts. BMJ 2010; 340: C1346.
4. Kondo K, Nozawa K, Tomira T, Ezaki K. Inbred strains resulting from Japanese mice. Bull Exp Anim 1957; 6: 107-12.
5. Igel M, Taylor BA, Phillips SJ, Becker W, Herberg L, Joost HG. Hyper-leptinemia and leptin receptor variant Asp600Asn in the obese, hyper-insulinemic KK mouse strain. J Mol Endocrinol 1998; 21: 337-45. (Pubitemid 29005405)
6. Ikeda H. KK mouse. Diabetes Res Clin Practice 1994; 24: S313-S316.
7. Nishimura. Breeding of mice strains for diabetes mellitus. Exp Animals 1969; 18: 147-57.
8. Iwatsuka H, Shino A, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinology 1970; 17: 23-35.
9. Klebig ML, Wilkinson JE, Geisler JG. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci U S A 1995; 92: 4728-32.
10. Stütz AM, Morrison CD, Argyropoulus G. The agouti-related protein and its role in energy homeostasis. Peptides 2005; 26: 1771-81. (Pubitemid 41354535)
11. Bray GA, York DA. Genetically transmitted obesity in rodents. Physiol Rev 1971; 51: 598-646.
12. Butler L, Gerritsen GC. A comparison of the modes of inheritance of diabetes in the Chinese hamster and the KK mouse. Diabetologia 1970; 6: 163-7.
13. Butler L. The inheritance of glucosuria in the KK and AY mouse. Can J Genet Cytol 1972; 14: 265-9.
14. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997; 21 Suppl 1: S25-9. (Pubitemid 27160696)
15. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805-75. (Pubitemid 30647075)
16. Matsumoto K, Iijima H. Sibutramine sensitivity assay revealed a unique phenotype of bombesin BB3 receptor-deficient mice. Eur J Pharmacol 2003; 473: 41-6. (Pubitemid 36857095)
17. Song GM, Huan Y, Sun SJ, Chen YT, Liu Q, Shen ZF. Biological activity of EXf, a peptide analogue of exendin-4. Eur J Pharmacol 2010; 628: 261-7.
18. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widman C. Cloning and functional expression of the GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin 3 (9-39) is an antagonist of the receptor. Diabetes 1993; 42: 1678-82 (Pubitemid 23318127)
19. Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science 1966; 153: 1127-8
20. Ingalls, AM, Dickie MM, Coleman DL. Obese, a new mutation in the house mouse. J Heredity 1950; 41: 317-8
21. Coleman DL. Effects of parabiosis of obese with diabetes and norma mice. Diabetologia 1973; 9: 294-8
22. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM Positional cloning of the mouse obese gene and its human homo-logue. Nature 1994; 372: 425-31
23. Frederich RC, Lollmann B, Hamann A, Napolitano-Rosen A, Kahn BB Lowell BB, et al. Expression of ob mRNA and its encoded protein in rodents, impact of nutrition and obesity. J Clin Invest 1995; 96 1658-63
24. Coleman DL, Hummel KP Obese gene in the mouse. Diabetologia 1973; 9: 287-93
25. Herberg L, Coleman DL. Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 1977; 26: 59-99 (Pubitemid 8027641)
26. Trayhurn P, Jones PM, McGuckin MM, Goodbody AE. Effects of overfeeding on energy balance and brown fat thermogenesis in obese (ob/ob) mice. Nature 1982; 295: 323-5 (Pubitemid 12159263)
27. Hogan S, Himms-Hagen J. Abnormal brown adipose tissue in obese (ob/ob) mice: response to acclimation to cold. Am J Physiol 1980 239: E301-E309 (Pubitemid 10008821)
28. Memon RA, Fuller J, Moser AH, Smith PJ, Grunfeld C, Feingold KR Regulation of putative fatty acid transporters and Acyl-CoA synthetase in liver and adipose tissue in ob/ob mice. Diabetes 1999; 48: 121-7 (Pubitemid 29019362)
29. Lindström P. β-Cell function in obese-hyperglycemic mice [ob/ob Mice] in the islets of Langerhans, advances in experimental medicine and biology, ed: Islam MS, 2010 654: 463-477, DOI 10.1007/978-90-481-3271-3-20
30. Lindström P. The physiology of obese-hyperglycemic mice [ob/ob Mice]. TheScientifcWorldJOURNAL 2007; 7:666-85 (Pubitemid 46850696)
31. Chua S, Herberg L, Leiter EH. Obesity/diabetes in mice with mutations in leptin or leptin receptor genes. In Shafrir E (ed). Anima models of Diabetes Frontiers in Research. London: Boca Raton, Fla CRC; 2007. p 61-102
32. Burcelin R, Kamohara S, Li J, Tannenbaum GS, Charron MJ, Friedman JM. Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake in ob/ob mice. Diabetes 1999 48: 1264-9 (Pubitemid 29241024)
33. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-3
34. Weigle DS, Bukowski TR, Foster DC, Holderman S, Kramer JM , Lasser G, et al. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest 1995; 96: 2065-70
35. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Benefcial effects of leptin on obesity, T cell hyporesponsiveness and neuroendocrine/metabolic dysfunction of human congenita eptin defciency. J Clin Invest 2002; 110: 1093-103 (Pubitemid 35215890)
36. Day C, Bailey CJ. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord 1998; 22: 619-23 (Pubitemid 28312770)
37. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-52
38. Irwin N, McClean PL, Cassidy RS, O'harte FP, Green BD, Gault VA et al. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. Diabetes Metab Res Rev 2007; 23: 572-9 (Pubitemid 350018032)
39. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-81. Erratum in Hepatology 2006; 44: 515 (Pubitemid 43733604)
40. Vergès B, Bonnard C, Renard E. Beyond glucose lowering: Glucagonike peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 2011. Doi : 10.1016/j.diabet.2011.07.001
41. Bode B. Liraglutide: a review of the frst once-daily GLP-1 receptor agonist. Am J Manag Care 2011; 17: S59-70
42. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, et al Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 1996; 13: 18-9
43. White BD, Martin RJ. Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proc Soc Exp Bio Med 1997; 214: 222-32
44. Artiñano AA, Castro MM. Experimental rat models to study the metabolic syndrome. Br J Nutr 2009; 102: 1246-53
45. Zucker TF, Zucker LM. Hereditary obesity in the rat associated with high serum fat and cholesterol. Proc Soc Exp Biol Med 1962; 110: 165-71
46. Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology 1972; 90: 1320-30
47. Bray GA. The Zucker-fatty rat: a review. Fed Proc 1977; 36: 148-53
48. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936-41 (Pubitemid 32274340)
49. Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE. Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 2000; 148: 231-41 (Pubitemid 30064454)
50. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983; 173: 68-75 (Pubitemid 13088195)
51. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin defciency. N Eng J Med 1999; 341: 879-84 (Pubitemid 29427050)
52. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC et al. Differential effects of fat and sucrose on the development of obesity and diabetes C57BL/6J and A/J mice. Metabolism 1995; 44: 645-51
53. West DB, Boozer CN, Moody DL, Atkinson RL. Dietary obesity in nine nbred mouse strains. Am J Physiol 1992; 262: R1025-R1032
54. West DB, Waguespack J, McCollister S. Dietary obesity in the mouse: nteraction of strain with diet composition. Am J Physiol 1995; 268: R658-R665
55. Schemmel R, Mickelsen O, Motawi K. Conversion of dietary to body energy in rats as affected by strain, sex and ration. J Nutr 1972; 102: 1187-97
56. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J, et al. Defning high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 2006; 36: 485-501 (Pubitemid 43904942)
57. Huang XF, Xin X, McLennan P, Storlien L. Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes Metab 2004; 6: 35-44 (Pubitemid 38159727)
58. Storlien LH, Higgins JA, Thomas TC, Brown MA, Wang HQ, Huang XF et al. Diet composition and insulin action in animal models. Br J Nutr 2000; 83 Suppl 1: S85-S90 (Pubitemid 30319087)
59. Delarue J, LeFoll C, Corporeau C, Lucas D. N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reprod Nutr Dev 2004 44: 289-99 (Pubitemid 39198971)
60. Wang H, Storlien LH, Huang XF. Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am J Physiol Endocrinol Metab 2002; 282 E1352-E1359 (Pubitemid 34654705)
61. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW. Infuence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 1991; 40: 280-9
62. Sato-Mito N, Suzui M, Yoshino H, Kaburagi T, Sato K. Long term effects of high fat and sucrose diets on obesity and lymphocyte proliferation in mice. J Nutr Health Aging 2009; 13: 602-6
63. Bray GA. Soft drink consumption and obesity: it is all about fructose Curr Opin Lipidol 2010; 21: 51-7
64. Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet Endocrinology 2010; 151: 2040-9
65. Couturier K, Batandier C, Awada M, Hininger-Favier I, Canini F Anderson RA, et al. Cinnamon improves insulin sensitivity and alters the body composition in an animal model of the metabolic syndrome Arch Biochem Biophys 2010; 501: 158-61
66. Shapiro A, Mu W, Roncal C, Cheng KY, Johnson RJ, Scarpace PJ Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1370-R1375
67. Sharma B, Henderson DC. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother 2008; 9: 2161-73
68. Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity 2011; 19 1342-9
69. Porter DW, Kerr BD, Flatt PR, Holscher C, Gault VA. Four weeks administration of liraglutide improves memory and learning as wel as glycaemic control in mice with high fat dietary-induced obesity and nsulin resistance. Diabetes Obes Metab 2010; 12: 891-9
70. Sclafani A, Springer D. Dietary obesity in adult rats: similarities to hypothalamic and human obesity syndromes. Physiol Behav 1976 17: 461-71
71. Rothwell NJ, Stock MJ. The cafeteria diet as a tool for studies of thermogenesis. J Nutrition 1988; 118: 925-8
72. Moore BJ. The cafeteria diet-an inappropriate tool for studies of thermogenesis. J Nutr 1987; 117: 227-31
73. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56: 8-15
74. Levin BE, Hogan S, Sullivan AC. Initiation and perpetuation of obesity and obesity resistance in rats. Am J Physsiol 1989; 256: R766-771
75. Madsen AN, Hansen G, Paulsen SJ, Lykkegaard K, Tang-Christensen M, Hansen HS, et al. Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenentic rat model mimick-ng the human obesity syndrome. J Endocrinol 2010; 206: 287-96
76. Levin BE, Keesey RE. Defense of differing weight set points in diet nduced obese and resistant rats. Am J Physiol 1998; 274: R412-9
77. Levin BE, Dunn-Meynell AA, Balkan B, Keesey RE. Selective breeding for diet-induced obesity and resistance in Spraque Dawley rats. Am J Physiol 1997; 273; R725-R730.
78. Cummings BP, Digitale EK, Stanhope KL, Graham JL, Baskin DG, Reed BJ, Sweet IR, Griffen SC, Havel PJ. Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1782-93.
79. Cummings BP, Digitale EK, Stanhope KL, Graham JL, Baskin DG, Reed BJ, et al. Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1782-93.
80. Cummings BP, Stanhope KL, Graham JL, Baskin DG, Griffen SC, Nilsson C, et al. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 2010; 59: 2653-61.
81. Bielschowsky M, Bielschowsky M. A new strain of mice with hereditary obesity. Proc Univ Otago Med School 1953; 31: 29-3.
82. Leiter EH, Reifsnyder PC. Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes 2004; 53 Suppl 1: S4-11. (Pubitemid 38168686)
83. Cho YR, Kim HJ, Park SY, Ko HJ, Hong EG, Higashimori T, et al. Hyperglycemia, maturity-onset obesity, and insulin resistance in NONcNZO10/LtJ males, a new mouse model of type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 293: E327-E336. (Pubitemid 47105948)
84. Koza RA, Flurkey K, Graunke DM, Braun C, Pan HJ, Reifsnyder PC, et al. Contributions of dysregulated energy metabolism to type 2 diabetes development in NZO/H1Lt mice with polygenic obesity. Metabolism 2004; 53: 799-808. (Pubitemid 38880915)
85. Pan HJ, Reifsnyder P, Vance DE, Xiao Q, Leiter EH. Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes. Diabetes 2005; 54: 1854-62. (Pubitemid 40770777)
86. Kim JH, Sen S, Avery CS, Simpson E, Chandler P, Nishina PM, et al. Genetic analysis of a new mouse model for non-insulin-dependent diabetes. Genomics 2001; 74: 273-86. (Pubitemid 32675351)
87. Rhee SD, Sung YY, Lee YS, Kim JY, Jung WH, Kim MJ, et al. Obesity of TallyHO/JngJ mouse is due to increased food intake with early development of leptin resistance. Exp Clin Endocrinol Diabetes 2011; 119: 243-51.
88. Bollen PJ, Madsen LW, Meyer O, Ritskes-Hoitinga J. Growth differences of male and female Göttingen minipigs during ad libitum feeding: a pilot study. Lab Animal 2005; 39: 80-93. (Pubitemid 40187699)
89. Raun K, von Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity 2007; 15: 1710-6. (Pubitemid 47264950)